Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy

The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelia...

Full description

Bibliographic Details
Main Authors:	Yong Jae Lee, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim
Format:	Article
Language:	English
Published:	MDPI AG 2020-04-01
Series:	Journal of Clinical Medicine
Subjects:	ovarian cancer radical surgery disease burden residual disease neoadjuvant chemotherapy
Online Access:	https://www.mdpi.com/2077-0383/9/4/1235

Similar Items

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
by: Yong Jae Lee, et al.
Published: (2022-07-01)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
by: Angeliki Andrikopoulou, et al.
Published: (2023-07-01)

Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: Retrospective Single-Center Study
by: Liliana Mereu, et al.
Published: (2023-10-01)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
by: Xingyu Liu, et al.
Published: (2023-06-01)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
by: Shi‐Ping Yang, et al.
Published: (2022-07-01)

Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes
by: Krystian Kaczmarek, et al.
Published: (2023-10-01)

Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy
by: Guillaume Ploussard, et al.
Published: (2020-06-01)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
by: Yong Jae Lee, et al.
Published: (2020-03-01)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
by: Mengmeng Lyu, et al.
Published: (2022-09-01)

Prognostic Value of Interval Between the Initiation of Neoadjuvant Treatment to Surgery for Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemotherapy, Radiotherapy and Definitive Surgery
by: Xiang-Bo Wan, et al.
Published: (2020-08-01)

Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study
by: Maričić Slobodan, et al.
Published: (2021-01-01)

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
by: Dengfeng Wang, et al.
Published: (2021-03-01)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
by: Ji-Yeon Kim, et al.
Published: (2022-06-01)

Optimal Timing of Surgery after Neoadjuvant Chemotherapy of Breast Cancer
by: Borna Farazmand, et al.
Published: (2017-03-01)

Interval Debulking Surgery for Advanced Ovarian Cancer in Elderly Patients (≥70 y): Does the Age Matter?
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals
by: Kobal Borut, et al.
Published: (2018-09-01)

Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma
by: Sarah Ali, et al.
Published: (2022-01-01)

Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery
by: Kevin W McCool, et al.
Published: (2018-10-01)

Adequate Pelvic Lymph Node Dissection in Radical Cystectomy in the Era of Neoadjuvant Chemotherapy: A Meta-Analysis and Systematic Review
by: Krystian Kaczmarek, et al.
Published: (2023-08-01)

Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy
by: Benedikt Hoeh, et al.
Published: (2022-02-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

Outcomes of neoadjuvant chemotherapy and radical hysterectomy for locally advanced cervical cancer at Kigali University Teaching Hospital, Rwanda: a retrospective descriptive study
by: Eugene Ngabonziza, et al.
Published: (2024-03-01)

Overall Survival Results with Surgical Treatment After Neoadjuvant Chemotherapy in Local Invasive Gastric Cancers
by: Gökhan Ertuğrul
Published: (2019-04-01)

Neoadjuvant chemotherapy with quick cisplatin-VP 16 followed by robotic radical trachelectomy in FIGO 2018 stage 1B2 cervical cancer
by: Ahra Lee, et al.
Published: (2022-05-01)

Survival outcomes and risk factors of patients with stage ⅡB cervical cancer undergoing neoadjuvant chemotherapy followed by radical hysterectomy
by: ZHOU Dan, et al.
Published: (2023-06-01)

The Outcomes of Primary Debulking Surgery and Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
by: Dino Rinaldy, et al.
Published: (2016-04-01)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
by: Naiki Taku, et al.
Published: (2012-12-01)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
by: Hiroko Miyagi, et al.
Published: (2022-12-01)

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
by: Ester Miralpeix, et al.
Published: (2022-02-01)

Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy
by: Qian H, et al.
Published: (2022-04-01)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
by: Takeshi Sasaki, et al.
Published: (2021-04-01)

The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer
by: Ciro Pinelli, et al.
Published: (2021-08-01)

The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
by: Oktay Üçer
Published: (2016-04-01)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
by: Ahmed Eldefrawy, et al.
Published: (2012-01-01)

Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience
by: Flavia Proietti, et al.
Published: (2024-02-01)

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis
by: Yi-Xin Zhou, et al.
Published: (2023-10-01)

Optimal Time Interval for Surgery After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer: Analysis of Health Insurance Review and Assessment Service Data
by: Min Jung Kim, et al.
Published: (2018-10-01)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
by: Yong Jae Lee, et al.
Published: (2022-05-01)

Perioperative Complications and Safety Evaluation of Robot-Assisted Radical Hysterectomy of Cervical Cancer After Neoadjuvant Chemotherapy
by: Chang WF, et al.
Published: (2020-06-01)

Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma
by: Makito Miyake, et al.
Published: (2019-12-01)